Sandoz Launches Generic Version Of Prograf Capsules In US
Tacrolimus, an immunosuppressive treatment to help prevent rejection of a kidney or liver transplant
Sandoz has launched tacrolimus capsules, a generic equivalent of Prograf, in the US. Tacrolimus is an immunosuppressive treatment to help prevent rejection of a kidney or liver transplant.
According to IMS Health, Prograf had US sales of $929m for the 12 months through April 2009. Sandoz will market tacrolimus in capsules of 0.5, 1 and 5mg strengths.
Jeff George, CEO of Sandoz, said: Tacrolimus is an important new product for Sandoz, further strengthening our diverse portfolio of affordable medicines in the key US market.
Sandoz is excited to offer this new high-quality, affordable treatment option to transplant patients. Sandoz and our parent company Novartis have deep experience in the transplant field and we are deeply committed to providing more cost-saving treatment options for this community in the future, he added.
Related Insight
Suppliers Directory
MeadWestvaco MWV - Healthcare Packaging and Dispensing Solutions
MWV is a global leader in healthcare packaging and packaging solutions.
Suppliers
Ellab – Thermal Validation Solutions
For more than 60 years Ellab A/S has been a leading manufacturer of process validation and monitoring systems used in the food, medical device and pharmaceutical industries. These systems monitor temperature, pressure and RH and are designed for validation applications that require compliance with FDA guidelines and international GMP standards. Ellab improves the quality of life by contributing to building confidence by providing solutions for measuring, recording, monitoring and validating critical parameters of thermal processing.
Suppliers
Chemetall - Tools for Organic Synthesis
Chemetall is a global company committed to specialty chemistry. The Lithium Division of Chemetall is the world’s leading supplier of Lithium compounds. Following to our expertise in this field of chemistry we also supply other organometallic compounds such as Grignard reagents, Amides and Alkoxides.
Suppliers
PDP Couriers - The Global Clinical Trials And Healthcare Specialist
With over 18 years experience PDP is a key specialist Courier company providing global solution-led logistics support services to Contract Research Organizations, Biopharmaceutical Companies and the Healthcare industry.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Contract Research > White Papers
Pharmacovigilance Services
Published by DOKUMEDS
White Papers
Pressure Mounts for Patient Access to Investigational Drugs
Published by CenterWatch
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.